EUVIMEDEUVIMED entdecken
Crossref

Targeting ATR Kinase as a Strategy for Canine Lymphoma and Leukaemia Treatment

Marta Henklewska iD, Aleksandra Pawlak iD, Bożena Obmińska-Mrukowicz

Veterinary and Comparative Oncology · 2024

DOI: 10.1111/vco.13014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, 2024. Verfasst von Marta Henklewska und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Wrocław University of Environmental and Life Sciences, Wrocław, Poland. Hauptthemen laut MEDLINE: Lymphoma, Dog Diseases, Ataxia Telangiectasia Mutated Proteins, Leukemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Science Centre, Poland, Narodowe Centrum Nauki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ataxia telangiectasia and Rad3‐related (ATR) kinase is one of the main regulators of cell response to DNA damage and replication stress. Effectiveness of ATR targeting in human cancers has been confirmed in preclinical studies and ATR inhibitors are currently developed clinically in human oncology. In the presented study, we tested the anticancer efficacy of ATR inhibitor berzosertib in an in vitro model of canine haematopoietic cancers. Using MTT assay and flow cytometry, we assessed the cytotoxicity of berzosertib in four established canine lymphoma and leukaemia cell lines and compared it with its activity against noncancerous canine cells. Further, we estimated the level of apoptosis in berzosertib‐treated cells via flow cytometry and assessed H2AX phosphorylation as a marker of DNA damage using western blot technique. In flow‐cytometric analysis, we also evaluated potential synergism between berzosertib and chlorambucil and assessed the influence of berzosertib on cell cycle disturbances induced by the drug. The results demonstrated that berzosertib, even without additional DNA damaging agent, can be effective against canine lymphoma and leukaemia cells at concentrations that were harmless for noncancerous cells, although sensitivity of individual cancer cell lines varied greatly. Cell death occurred through caspase‐dependent apoptosis via induction of DNA damage. Berzosertib also acted synergistically with chlorambucil, probably by preventing DNA damage repair as a consequence of S‐phase arrest abrogation. In conclusion, ATR inhibition may provide a new therapeutic option for the treatment of canine lymphomas and leukaemias, but further studies are required to determine potential biomarkers of their susceptibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphomaDog DiseasesAtaxia Telangiectasia Mutated ProteinsLeukemiaDogsAnimalsCell Line, TumorAntineoplastic AgentsApoptosisDNA DamageChlorambucilIsoxazolesPyrazines

Stichwörter der Autor:innen

ATR inhibitionDNA damageberzosertibcancer therapycanine cancer

Substanzen

Ataxia Telangiectasia Mutated ProteinsberzosertibAntineoplastic AgentsChlorambucilIsoxazolesPyrazines

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Wrocław University of Environmental and Life Sciences, Wrocław, Poland.

ORCID-Profile: Marta Henklewska, Aleksandra Pawlak

Förderung

  • National Science Centre, Poland
  • Narodowe Centrum Nauki

Zitieren

APA

Henklewska, M., Pawlak, A., & Obmińska-Mrukowicz, B. (2024). Targeting ATR Kinase as a Strategy for Canine Lymphoma and Leukaemia Treatment. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.13014

Vancouver

Henklewska M, Pawlak A, Obmińska-Mrukowicz B. Targeting ATR Kinase as a Strategy for Canine Lymphoma and Leukaemia Treatment. Veterinary and Comparative Oncology. 2024. doi:10.1111/vco.13014

BibTeX
@article{Henklewska2024,
  author = {Henklewska, Marta and Pawlak, Aleksandra and Obmińska-Mrukowicz, Bożena},
  title = {Targeting ATR Kinase as a Strategy for Canine Lymphoma and Leukaemia Treatment},
  journal = {Veterinary and Comparative Oncology},
  year = {2024},
  doi = {10.1111/vco.13014}
}
Kostenlos starten →